search
Back to results

SQ53 Disinfectant Wipes for Prevention of CRBSI

Primary Purpose

Catheter-related Bloodstream Infection

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
SQ53 Wipe
Ethanol Wipe
Sponsored by
The Cleveland Clinic
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Catheter-related Bloodstream Infection

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients requiring home parenteral nutrition support via PICC line or tunneled CVC.

Exclusion Criteria:

  • Age less than 18 years
  • Women known to be pregnant
  • Women of childbearing age who are planning a pregnancy
  • Women who are breastfeeding
  • Patients who will not be managed by Cleveland Clinic HPN service
  • Patients who refuse to use disinfectant wipes daily.

Sites / Locations

  • Cleveland Clinic

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Standard Wipe

SQ53 Wipe

Arm Description

Participants will receive a supply of ethanol-based wipes for daily use

Participants will receive a supply of SQ53 wipes for daily use.

Outcomes

Primary Outcome Measures

Number of Catheter-Related Blood Stream Infections (CRBSI) at 6 Months
Reduction in the number of CRBSI experienced by participants over a six month period (1000 days)

Secondary Outcome Measures

Catheter Exchange Rates
Reduction in catheter exchange rates by participants over 1000 days

Full Information

First Posted
March 26, 2021
Last Updated
May 5, 2023
Sponsor
The Cleveland Clinic
Collaborators
JVS Products, Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT04822467
Brief Title
SQ53 Disinfectant Wipes for Prevention of CRBSI
Official Title
SQ53 Disinfectant Wipes for Prevention of Catheter Related Blood Stream Infection in Patients Receiving Home Parenteral Nutrition: A Single Blind Randomized Placebo-controlled Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Completed
Study Start Date
December 10, 2021 (Actual)
Primary Completion Date
December 7, 2022 (Actual)
Study Completion Date
December 7, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
The Cleveland Clinic
Collaborators
JVS Products, Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
SQ53 is a novel antimicrobial, sporicidal solution that is based on a platform of quaternary ammonium chloride compounds. It has been tested against a wide range of bacteria, viruses, spores and fungal pathogens. Extensive laboratory testing has demonstrated the effectiveness of SQ53 impregnated wipes in cleaning surfaces including catheters over a 24 hour plus time period. SQ53 also received an in vitro evaluation of the irritancy potential using a tissue engineered human skin model and was found to have no potential for skin irritation. SQ53 is available as a sterilized pack with a single wipe inside. The pack is easy to open by tearing off the top end and presenting the contents to the operator to remove under sterile conditions. The current study will be a randomized single-blinded placebo-controlled clinical trial for SQ53 wipes intended for catheter cleaning in patients receiving home parenteral nutrition.
Detailed Description
Parenteral nutrition (PN) therapy is an essential component of medical management of patients suffering from intestinal failure. Depending on the underlying etiology and the type of intestinal failure, the duration of parenteral nutrition therapy could range from several weeks to several years, although a substantial proportion of these patients also require lifelong parenteral nutrition support. These patients continue the infusion of PN at their homes and are managed by the Cleveland Clinic's Home PN support team. These patients require Central Venous Catheters (CVC) for prolonged period of time for infusion of parenteral nutrition. The two most commonly used central catheters for TPN infusion are the Peripherally Inserted Central Catheter (PICC) and Tunneled CVCs. Catheter related blood stream infection (CRBSI) is a major complication of long-term CVCs. CRBSI is associated with high morbidity, mortality and healthcare cost. Additionally, CRBSI can also lead to an interruption in nutrient delivery, loss of work and productivity, premature vascular access device removal, and poor quality of life. Prevention of CRBSI is an important component of clinical management of patients receiving home PN therapy. Several strategies have been adopted to reduce the incidence of CRBSI. A heparin lock solution was used in the past for many years; however, current nutrition society guidelines recommend normal saline locks instead of heparin locks. Published data has suggested that heparin locks have not proven to have a substantial effect on CRBSI prevention, and it paradoxically increases the infection risk due to biofilm production. Antibiotic locks have also been used, although this practice is largely not preferred due to increased risk of infections with resistant microorganisms. Taurolidine is another lock solution which has been studied in the countries outside the United States such as Canada; however, it has not been approved for the use in the U.S. yet.1

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Catheter-related Bloodstream Infection

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Investigator
Allocation
Randomized
Enrollment
59 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Standard Wipe
Arm Type
Active Comparator
Arm Description
Participants will receive a supply of ethanol-based wipes for daily use
Arm Title
SQ53 Wipe
Arm Type
Experimental
Arm Description
Participants will receive a supply of SQ53 wipes for daily use.
Intervention Type
Device
Intervention Name(s)
SQ53 Wipe
Intervention Description
SQ53-based wipe to be used by the participant daily or upon dressing change
Intervention Type
Device
Intervention Name(s)
Ethanol Wipe
Intervention Description
Ethanol-based wipe to be used by the participant daily or upon dressing change
Primary Outcome Measure Information:
Title
Number of Catheter-Related Blood Stream Infections (CRBSI) at 6 Months
Description
Reduction in the number of CRBSI experienced by participants over a six month period (1000 days)
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Catheter Exchange Rates
Description
Reduction in catheter exchange rates by participants over 1000 days
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients requiring home parenteral nutrition support via PICC line or tunneled CVC. Exclusion Criteria: Age less than 18 years Women known to be pregnant Women of childbearing age who are planning a pregnancy Women who are breastfeeding Patients who will not be managed by Cleveland Clinic HPN service Patients who refuse to use disinfectant wipes daily.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Donald Kirby, MD
Organizational Affiliation
The Cleveland Clinic
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cleveland Clinic
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44195
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

SQ53 Disinfectant Wipes for Prevention of CRBSI

We'll reach out to this number within 24 hrs